Head-To-Head Comparison: Inotiv (NASDAQ:NOTV) versus Sandoz Group (OTCMKTS:SDZNY)

Inotiv (NASDAQ:NOTV) and Sandoz Group (OTCMKTS:SDZNY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Institutional and Insider Ownership

18.2% of Inotiv shares are owned by institutional investors. Comparatively, 0.1% of Sandoz Group shares are owned by institutional investors. 7.8% of Inotiv shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Inotiv and Sandoz Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inotiv	-13.50%	-28.95%	-5.22%
Sandoz Group	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and price targets for Inotiv and Sandoz Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inotiv	1	0	1	0	2.00
Sandoz Group	0	2	0	2	3.00

Inotiv presently has a consensus target price of $1.50, suggesting a potential upside of 401.67%. Given Inotiv’s higher possible upside, analysts clearly believe Inotiv is more favorable than Sandoz Group.

Earnings & Valuation

This table compares Inotiv and Sandoz Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inotiv	$513.02 million	0.02	-$68.62 million	($2.03)	-0.15
Sandoz Group	$11.09 billion	3.24	$914.00 million	N/A	N/A

Sandoz Group has higher revenue and earnings than Inotiv.

Risk and Volatility

Inotiv has a beta of 4.07, meaning that its stock price is 307% more volatile than the S&P 500. Comparatively, Sandoz Group has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Summary

Sandoz Group beats Inotiv on 8 of the 13 factors compared between the two stocks.

About Inotiv

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.